Review of NICE Technology Appraisal Guidance no. 100; Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes' C) colon cancer

As you may be aware the planned date for review of the above guidance was June 2009.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

Having re-run the search strategy from the original assessment report the Institute has not found any relevant additions to the evidence base that would have a material effect on the guidance. The evidence available concerning capecitabine and oxaliplatin has not significantly changed. Consequently, we propose that the original guidance become static.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial.  Please see appendix A for a full list of the organisations we have contacted.

Please note all comments received will be published on the Institute’s website when a decision has been made.